BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BMN 333 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BMN 333\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07441876-10781@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:BMN 333: Phase 2/3 readout est. (NCT07441876)
DESCRIPTION:BMN 333\, phase 2/3\, Achondroplasia.\nStudy: Study to Evaluate
  the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Ach
 ondroplasia\nEstimated primary completion: June 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bmn-333#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07441876
URL:https://assetmemo.bio/drug/bmn-333#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
